Chatterjee Prabal Kumar
Department of Pharmacology and Therapeutics, School of Pharmacy and Biomolecular Sciences, University of Brighton, Cockcroft Building, Moulsecoomb, Brighton BN2 4GJ.
Br J Pharmacol. 2004 Jun;142(3):391-3. doi: 10.1038/sj.bjp.0705826. Epub 2004 May 17.
Carbon monoxide (CO) is formed during the degradation of haeme by haeme oxygenase (HO). As well as being an important signalling molecule and vasodilator, CO also possesses antihypertensive, anti-inflammatory and antiapoptotic qualities and protects against ischaemic tissue injury. Several approaches have been used to investigate the therapeutic potential of CO, ranging from direct administration of CO gas to the use of prodrugs, which generate CO upon metabolism. A novel approach involves the use of specific CO carriers, which will release measurable, controllable and effective amounts of CO into biological systems. Transitional metal carbonyls based around iron, manganese or ruthenium have recently been developed as CO-releasing molecules (CO-RMs) that, under appropriate conditions, will release CO. Such molecules have been shown to provide cardioprotection in both ex vivo and in vivo experiments. To date, CO-RMs have been largely incompatible with biological systems in that they are only soluble in organic solvents or have to be preactivated either by physical or chemical stimuli. However, the recent development of water-soluble CO-RMs has provided new opportunities to investigate the pharmacological and biological features of CO without such confounding influences. CORM-3, a novel water-soluble CO-RM, has recently been used to confirm the cardioprotective actions of CO. In this issue of British Journal of Pharmacology, Foresti and co-workers report that CORM-3 delivers CO, produces aortic vasodilation ex vivo and reduces blood pressure in vivo via modulation of the same cGMP and potassium channels utilised by endogenous and exogenous CO. These findings suggest that CORM-3 has the potential for use as a modulator of vascular function and hypertension. However, the use of water-soluble CO-RMs raises several questions of their own which will need to be addressed if CO-RMs are to be of future use therapeutically.
一氧化碳(CO)由血红素加氧酶(HO)降解血红素时形成。CO不仅是一种重要的信号分子和血管舒张剂,还具有抗高血压、抗炎和抗凋亡特性,并能预防缺血性组织损伤。人们采用了多种方法来研究CO的治疗潜力,从直接给予CO气体到使用前体药物,前体药物在代谢时会产生CO。一种新方法涉及使用特定的CO载体,这种载体能将可测量、可控制且有效的CO释放到生物系统中。最近,基于铁、锰或钌的过渡金属羰基化合物已被开发为CO释放分子(CO-RMs),在适当条件下会释放CO。此类分子已在体外和体内实验中显示出具有心脏保护作用。迄今为止,CO-RMs在很大程度上与生物系统不兼容,因为它们仅溶于有机溶剂,或者必须通过物理或化学刺激进行预激活。然而,水溶性CO-RMs的最新进展为研究CO的药理和生物学特性提供了新机会,而不会受到此类混杂因素的影响。新型水溶性CO-RM CORM-3最近已被用于证实CO的心脏保护作用。在本期《英国药理学杂志》中,福雷斯蒂及其同事报告称,CORM-3能释放CO,在体外使主动脉血管舒张,并通过调节内源性和外源性CO所利用的相同环磷酸鸟苷(cGMP)和钾通道在体内降低血压。这些发现表明,CORM-3有潜力用作血管功能和高血压的调节剂。然而,水溶性CO-RMs的使用也引发了一些自身问题,如果要在未来将CO-RMs用于治疗,这些问题需要得到解决。